Mounjaro (tirzepatide) Letter of Medical Necessity
Mounjaro (tirzepatide) is a newer dual GIP/GLP-1 agonist that frequently faces step therapy hurdles requiring failure of a single-mechanism GLP-1 first. LMNs should emphasize objective metabolic targets and SURPASS trial superiority data. For complete 2026 payer criteria, see our GLP-1 Prior Authorization Guide.
FDA-Approved Indications
- ● type 2 diabetes mellitus
Why Mounjaro Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Step therapy: GLP-1 not tried first
- 2. A1c criterion not met
- 3. Off-label use for obesity (Zepbound is the approved formulation)
- 4. Formulary exclusion in favor of preferred GLP-1
- 5. Specialty tier cost-share challenge
What to Include in a Mounjaro Letter of Medical Necessity
Document T2DM, current A1c relative to individualized target, prior GLP-1 trial outcomes (if applicable), and weight comorbidities. Cite SURPASS-2 head-to-head data when challenging step therapy that mandates semaglutide first.
Key clinical evidence to cite:
- ✓ SURPASS-1 through SURPASS-5 trials
- ✓ Head-to-head superiority over semaglutide in SURPASS-2
- ✓ Greater A1c and weight reduction than mono-mechanism GLP-1s
Relevant guidelines:
- 📖 ADA 2024 Standards of Care
- 📖 AACE 2022 Algorithm
Mounjaro Prior Authorization Criteria
Standard criteria across major US payers for Mounjaro. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Step therapy: GLP-1 not tried first
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Mounjaro
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Mounjaro Prior Authorization FAQ
Why was my Mounjaro prior authorization denied?
The most common denial reasons for Mounjaro are: Step therapy: GLP-1 not tried first; A1c criterion not met; Off-label use for obesity (Zepbound is the approved formulation); Formulary exclusion in favor of preferred GLP-1; Specialty tier cost-share challenge.
What should a Mounjaro Letter of Medical Necessity include?
Document T2DM, current A1c relative to individualized target, prior GLP-1 trial outcomes (if applicable), and weight comorbidities. Cite SURPASS-2 head-to-head data when challenging step therapy that mandates semaglutide first.
Which payers cover Mounjaro?
Mounjaro is covered by major US payers including UnitedHealthcare, Aetna, Cigna, Anthem, Humana, though formulary tier and prior authorization criteria vary.